1. Diabetes Monotherapies versus Metformin-Based Combination Therapy for the Treatment of Type 2 Diabetes
- Author
-
Singh AK, Singh R, and Chakraborty PP
- Subjects
type 2 diabetes ,monotherapy ,combination therapies ,efficacy ,safety outcomes ,Medicine (General) ,R5-920 - Abstract
Awadhesh K Singh,1 Ritu Singh,1 Partha Pratim Chakraborty2 1Department of Diabetes & Endocrinology, G.D Hospital & Diabetes Institute, Kolkata, India; 2Department of Endocrinology & Metabolism, Medical College, Kolkata, IndiaCorrespondence: Awadhesh K SinghG.D Hospital & Diabetes Institute, Kolkata, 700014, IndiaTel +91 9831020428Email draksingh_2001@yahoo.comAbstract: Step-wise addition of antihyperglycemic agents (AHA) after the initiation of metformin monotherapy has been the traditional approach for the treatment of type 2 diabetes mellitus (T2DM) world-wide. Emerging evidence increasingly suggests that metformin-based combination therapy, especially with the newer AHA that lowers HbA1c glucose-dependently and do not potentiate hypoglycemia, could be a potentially better option for durable glycemic control with good tolerability compared to diabetes monotherapy. In this review, we descriptively analyzed the evidence available from the systematic reviews and meta-analyses of randomized head-to-head trials that reported the efficacy and safety outcomes of diabetes monotherapy, metformin-based combination therapies, and monotherapy versus metformin-based combination therapies.Keywords: type 2 diabetes, monotherapy, combination therapies, efficacy, safety outcomes
- Published
- 2021